Catalyst Pharmaceuticals, Inc. CPRX
We take great care to ensure that the data presented and summarized in this overview for CATALYST PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CPRX
View all-
Black Rock Inc. New York, NY18.7MShares$401 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$119 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$73.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$67.3 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.96MShares$63.4 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA2.77MShares$59.3 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.39MShares$51.4 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.19MShares$46.9 Million0.01% of portfolio
-
Terry Smith Fundsmith LLP | London, X02.15MShares$46.1 Million0.24% of portfolio
Latest Institutional Activity in CPRX
Top Purchases
Top Sells
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Transactions at CPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,600
-3.75%
|
$41,600
$26.42 P/Share
|
|
Jun 10
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,324
-5.16%
|
$60,424
$26.41 P/Share
|
|
Jun 09
2025
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
171,748
-3.86%
|
$4,465,448
$26.11 P/Share
|
|
Jun 06
2025
|
Patrick J Mcenany Director |
SELL
Open market or private sale
|
Direct |
28,252
-0.63%
|
$706,300
$25.95 P/Share
|
|
May 30
2025
|
Richard J Daly President and CEO |
BUY
Open market or private sale
|
Direct |
70,000
+25.95%
|
$1,680,000
$24.86 P/Share
|
|
May 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
44,000
-38.98%
|
$1,012,000
$23.63 P/Share
|
|
May 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,000
+28.05%
|
$176,000
$4.64 P/Share
|
|
May 13
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
200,000
-74.38%
|
$4,600,000
$23.68 P/Share
|
|
May 13
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+42.66%
|
$600,000
$3.42 P/Share
|
|
Mar 06
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
180,096
-72.34%
|
$3,782,016
$21.67 P/Share
|
|
Mar 06
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
180,096
+41.97%
|
$360,192
$2.24 P/Share
|
|
Mar 05
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
44,904
-39.47%
|
$987,888
$22.09 P/Share
|
|
Mar 05
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,904
+28.3%
|
$89,808
$2.24 P/Share
|
|
Mar 03
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
30,423
-100.0%
|
$669,306
$22.89 P/Share
|
|
Mar 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
62,975
-13.46%
|
$1,448,425
$23.08 P/Share
|
|
Mar 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,525
+11.26%
|
$125,050
$2.24 P/Share
|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,353
-1.23%
|
-
|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,667
+4.82%
|
-
|
|
Feb 14
2025
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.54%
|
-
|
|
Feb 14
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,965
-11.7%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2.21M shares |
|---|---|
| Open market or private sale | 70K shares |
| Payment of exercise price or tax liability | 50.4K shares |
|---|---|
| Open market or private sale | 2M shares |
| Bona fide gift | 50.1K shares |